The AHA today commented on the Food and Drug Administration’s draft guidance for industry and FDA staff on clinical decision support software as part of the agency’s efforts to implement Section 3060(a) of the 21st Century Cures Act. AHA expressed concern that “FDA’s interpretation of certain criteria could result in many existing CDS algorithms being subject to the FDA approval process and ultimately slow the pace of innovation and development of new algorithms to support better patient care and outcomes.” In its letter, AHA shared specific recommendations with FDA and said it “looks forward to working with the FDA to ensure the agency’s regulatory approach to implementing Section 3060(a) is consistent with the language and intent of the Cures Act and prioritizes patient safety while at the same time allowing hospitals and health systems to continue to implement innovative decision support tools.”

Related News Articles

Blog
Raul Yzaguirre on September 14, 2022 at the UnidosUS ceremony honoring him.   Hispanic Heritage Month is Sept. 15 through Oct. 15, an annual time to…
Headline
Former AHA Chair and Distinguished Service Award recipient Sister Mary Roch Rocklage passed away yesterday. She was 87.      Rocklage was…
#HealthCareInnovation Thursday Blog
Situated in the heart of Westchester County and just outside of New York City, White Plains Hospital was among the first hospitals in New York to face the…
#HealthCareInnovation Thursday Blog
Like many hospitals and health systems across the nation, the AdventHealth Central Florida Division is experiencing a shortage of nurses. According to the…
Headline
The Department of Health and Human Services has reopened to new signatories until Oct. 28 the agency's voluntary initiative for health sector…
#HealthCareInnovation Thursday Blog
Recently, nearly 1,000 health care leaders and changemakers convened at Aspen Ideas: Health, part of the Aspen Institute’s Aspen Ideas Festival, to explore…